Levothyroxine

Prohormone Conversion via Peripheral Deiodinases#

Levothyroxine is synthetic T4 — a prohormone with weak intrinsic activity. The real work happens after absorption, when type 1 and type 2 deiodinases (DIO1, DIO2) strip an iodine off the outer ring in liver, kidney, skeletal muscle, brown fat, and CNS tissue, yielding the biologically active T3. DIO3 diverts a fraction down the reverse-T3 (rT3) pathway, which is inactive and acts as a metabolic brake under stress or aggressive dieting.

"The type 1 and type 2 deiodinases convert the prohormone T4 to the active hormone T3 in peripheral tissues, thereby locally controlling T3 production and thyroid hormone signaling." — Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Endocrine Reviews, 2002

This tissue-by-tissue conversion is why T4 feels "smoother" than direct T3: each tissue regulates its own local T3 supply rather than being hit with a systemic pulse. It's also why T4 takes 4–6 weeks to express its full effect — you're not dosing the active hormone, you're feeding the conversion pool.

Nuclear Receptor Signalling and Metabolic Gene Expression#

Once generated, T3 crosses into the nucleus and binds thyroid hormone receptors (TRα1, TRβ1, TRβ2), which heterodimerize with RXR on thyroid response elements (TREs). This drives transcription of the genes that matter for physique users:

• Na⁺/K⁺-ATPase and mitochondrial uncoupling proteins → higher basal metabolic rate and thermogenesis
• Mitochondrial biogenesis → increased oxidative capacity
• β-adrenergic receptor density in adipocytes → greater sensitivity to catecholamines, clen, and yohimbine
• Hormone-sensitive lipase activity → accelerated lipolysis

The practical translation: T4 doesn't burn fat directly, it raises the ceiling on every other fat-loss tool you're running. Cardio burns more, clen hits harder, caloric deficits produce cleaner weight loss instead of stalling out.

Non-Genomic Membrane Signalling#

Not all thyroid effects run through the nucleus. T4 and T3 bind integrin αvβ3 on the plasma membrane, triggering rapid PI3K/MAPK signalling within minutes. This is responsible for the acute cardiovascular effects — positive chronotropy, increased contractility, peripheral vasodilation — that show up well before gene transcription could explain them. It's also why resting heart rate is the single best at-home marker for whether your T4 dose is in range: if resting HR is +15 bpm over baseline, the dose is excessive regardless of labs.

HPT Axis Suppression#

Exogenous T4 suppresses hypothalamic TRH and pituitary TSH via negative feedback within 2–4 weeks of consistent dosing. Endogenous thyroid output drops accordingly. Recovery after discontinuation takes 4–8 weeks in healthy users — slower than HPTA recovery from most AAS — which is why tapering (25 mcg every 5–7 days) and a post-cycle low-dose bridge matter more here than they would for a compound with a shorter axis-recovery curve.

Protein Turnover: The Catabolism Caveat#

T3 upregulates both protein synthesis AND protein breakdown. At replacement doses the two track roughly in balance. Push into supraphysiologic territory — 150+ mcg T4/day in a lean user, or any T3 stack — and breakdown wins in skeletal muscle. This is the core reason physique users running thyroid on a cut almost always pair it with sufficient testosterone (≥200–400 mg/week) and keep protein at ≥1 g/lb; the AAS floor offsets the catabolic tilt and lets you keep the fat-loss benefit without eating your quads.

Pharmacokinetic Profile That Shapes Protocol#

T4's ~7-day half-life (https://pubmed.ncbi.nlm.nih.gov/29922349/) is the defining feature separating it from T3 in practice. Stable serum levels, forgiving missed-dose behaviour, and a slow approach to steady state — but also a slow response to dose changes.

"Levothyroxine (L-T4) is characterised by an oral bioavailability of between 60 % and 80 %, with maximum serum concentrations observed around 2–4 hours post-dose. Its half-life is in the range of 6–7 days in euthyroid subjects." — Colucci P, Yue CS, Ducharme M, Benvenga S. European Endocrinology, 2013

The protocol implications are concrete: dose once daily, fasted on waking with water only, then push food and coffee out 30–60 minutes. Coffee alone cuts absorption ~30% when taken concurrently, and calcium/iron/PPIs are worse. Don't bump the dose before week 6 — you haven't seen steady state yet, and impatient users routinely overshoot because they evaluated a dose at week 2 and moved up.

Common (most users)#

• Elevated resting heart rate — +5–15 bpm is expected above physiologic replacement. Check resting HR every morning before dosing; if it climbs >15 bpm over baseline or crosses ~85 bpm at rest, drop 25 mcg and hold for 2 weeks before reassessing. Avoid stacking with high-dose clen, ephedrine, or yohimbine simultaneously.
• Insomnia / sleep disruption — dose on waking, never in the evening. The 7-day half-life means timing doesn't affect serum levels much, but the sympathetic tone from a fresh dose can delay sleep onset if taken late.
• Heat intolerance, mild sweating — expected feedback that dose is active. Hydrate aggressively (3–4 L/day on cut) and add electrolytes; physiologic, not pathologic.
• Loose stools, increased GI transit — usually settles in 2–3 weeks. If persistent, split dose or reduce by 25 mcg.
• Mild tremor, jitteriness — most noticeable in first 2 weeks and when stacked with beta-agonists. Back the beta-agonist off before the T4.
• Reduced absorption from food / coffee / supplements — not a side effect so much as a protocol failure. Take fasted with water only, then wait 30–60 minutes before coffee, food, calcium, iron, magnesium, or any PPI/H2 blocker.

"Levothyroxine should be administered on an empty stomach, at least 30 to 60 minutes before breakfast or at bedtime (at least 3 hours after the last meal), to achieve optimal and consistent absorption." — Skelin et al., Clinical Therapeutics (2017)

"Coffee interferes with intestinal absorption of L-thyroxine, reducing its oral bioavailability when ingested together." — Benvenga et al., Thyroid (2008)

Uncommon (dose-dependent or individual)#

• Muscle catabolism — the single biggest concern for physique users at supraphysiologic doses. Mitigation: keep AAS support at minimum 200–400 mg/week testosterone, protein ≥1 g/lb, avoid aggressive (>500 kcal) deficits while on T4, and don't exceed 125 mcg without a clear reason.
• Anxiety, irritability, racing thoughts — dose-dependent. If present at 125 mcg+, back down to 100 mcg and let steady state re-establish over 4–6 weeks before judging.
• Palpitations / ectopic beats — occasional PVCs are common with supraphysiologic T4; frequent or symptomatic palpitations are a stop signal. Check TSH, fT3, fT4, and potassium.
• Hair shedding — paradoxically can occur both from under- and over-replacement, typically 6–10 weeks after a dose change. Hold dose steady, recheck labs at week 6.
• Cycle irregularity in women — supraphysiologic dosing can disrupt menses. Women running T4 for physique should dose conservatively (50–100 mcg) and check TSH at 6 weeks.
• SHBG elevation — T4 accelerates SHBG synthesis, which can lower free testosterone and shift cycle interpretation. Worth factoring into bloodwork when reading TRT/cycle labs.

Bloodwork checkpoints: TSH, fT4, fT3, rT3 at baseline, week 6 (steady state), and every 6–8 weeks thereafter. A suppressed TSH with high-normal fT4 and normal fT3 is the typical "on protocol" pattern; if fT3 runs above range, you're overshot regardless of how you feel.

Rare but serious#

• Atrial fibrillation — risk rises sharply with age >50, pre-existing structural heart disease, and stacking with AAS-induced LVH or high-dose sympathomimetics. Warning signs: sustained irregular pulse, chest pressure, breathlessness climbing stairs. Stop immediately and get an ECG.
• Angina / ischemic chest pain — T4 increases myocardial oxygen demand; in users with undiagnosed coronary disease, this can unmask ischemia. Any exertional chest pain on T4 is a hard stop.
• Thyrotoxicosis — from stacking errors (double-dosing, adding T3 without reducing T4, or combining with an undiagnosed autonomous nodule). Presents as HR >110 at rest, tremor, heat intolerance, diarrhea, weight loss disproportionate to deficit. Discontinue and check fT3/fT4.
• Adrenal crisis — in users with undiagnosed adrenal insufficiency, T4 accelerates cortisol clearance and can precipitate crisis (hypotension, collapse, vomiting). Rare but lethal — see contraindications.
• Reduced bone density — only relevant for chronically suppressive dosing (TSH <0.1 for years), not 6–10 week physique cycles. Worth knowing if you're running T4 indefinitely as part of a GH-axis stack.

Hard contraindications#

• Untreated adrenal insufficiency — T4 can precipitate adrenal crisis. Address cortisol status before starting.
• Recent myocardial infarction, active ischemic heart disease, or uncontrolled arrhythmia — T4 increases cardiac workload; do not use.
• Untreated hypertension — get BP controlled first. T4 on top of uncontrolled HTN plus AAS is a stroke setup.
• Pre-existing hyperthyroidism, Graves' disease, or toxic multinodular goiter — additive to endogenous excess.
• Do not stack supraphysiologic T4 with high-dose clenbuterol plus Tren simultaneously — the combined sympathetic and cardiac load (resting HR 100+, insomnia, arrhythmia risk) is not worth the marginal fat-loss gain. Pick two of the three.
• Pregnancy / active attempts to conceive — physiologic replacement is fine and indicated where needed, but supraphysiologic fat-loss dosing is inappropriate. Stop well before conception attempts and dose only to TSH.

Gender, PCT, and recovery notes#

Levothyroxine does not interact with the HPG axis and requires no PCT. Women can use the same microgram ranges as men — dose to labs (TSH, fT3, fT4), not to body weight. Pregnancy is not a contraindication to replacement dosing, but supraphysiologic "cutting" doses are. After any cycle >4 weeks, taper 25 mcg every 5–7 days rather than cold-stopping — endogenous thyroid output is suppressed and takes 4–8 weeks to recover, which can feel like a prolonged post-cycle fatigue if you drop the dose abruptly. A 4–6 week T4 bridge at 50–75 mcg after a T3 cycle is the cleanest way to avoid the post-T3 crash.